Karyopharm Therapeutics INC 10-Q quarterly reports

Karyopharm Therapeutics Inc. reported substantial doubt about its ability to continue as a going concern, citing significant operating losses and upcoming debt obligations, despite a slight increase in net product revenue.

Karyopharm Therapeutics Inc. announced its first quarter 2026 financial results, highlighting increased product revenue and ongoing clinical development efforts.

Karyopharm Therapeutics Inc. reported a net loss of $93.8 million for the nine months ended September 30, 2025, but secured $36 million in new financing and debt deferrals in October 2025 to address substantial doubt about its ability to continue as a going concern.

Karyopharm Therapeutics reported a significant net loss in Q2 2025 and disclosed substantial doubt about its ability to continue as a going concern, prompting a review of strategic alternatives.

Karyopharm Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern within the next year.

Karyopharm Therapeutics' Q3 2024 results show a mixed financial picture with decreased product revenue offset by increased license revenue, while the company navigates substantial debt restructuring and going concern challenges.

Karyopharm Therapeutics announced its second quarter 2024 financial results, highlighted by a gain on debt extinguishment and a strategic refinancing.

Karyopharm Therapeutics reported a net loss for Q1 2024, while also announcing a significant debt refinancing to extend maturities and improve working capital.